Creative Biolabs Enhances mRNA Immunotherapy Platform for Preclinical Research

Creative Biolabs has expanded its mRNA immunotherapy development services, establishing a comprehensive platform for advanced preclinical research. This system provides temporary genetic instructions to cells for producing various immune-modulating proteins, antigens, or antibodies, offering an alternative to traditional protein-focused methods.

The company's offerings include customized mRNA design and optimization, alongside strategies for effective delivery and validation support. A significant focus addresses the challenge of mRNA delivery, with services like polymer vector development utilizing polyplex and micelleplex platforms, tailored to specific research needs and payload properties.

Beyond delivery, the platform supports the study of molecular mechanisms regulating RNA within cells. Creative Biolabs provides CLIP-Seq RNA-protein interaction analysis to map binding sites and interpret bioinformatics data, aiding researchers in understanding post-transcriptional regulation and optimizing immune responses.

Further enhancing its capabilities, Creative Biolabs offers antibody-encoding mRNA products, allowing cells to express antibody proteins or fragments transiently. These products, featuring various modification strategies, cap structures, and poly(A) tail designs, support studies in antibody mechanisms, gene expression, and exploratory therapeutic development.